| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌 | CN201180039874.2 | 2011-06-16 | CN103189504B | 2017-05-24 | T.R.克莱恩哈默; E.普菲勒; M.莫哈马扎德 |
| 提供用于治疗或预防炎性病症的方法和组合物。本发明组合物包含经遗传修饰以减少细胞表面上脂磷壁酸展示的重组细菌。本发明方法包括给予受试者经修饰以减少细胞表面上脂磷壁酸展示的重组细菌。给予所述重组细菌促进所需的治疗反应。所述重组细菌可以以单独剂量或系列剂量给予。本发明方法在治疗或预防多种炎性病症包括，例如，治疗或预防炎性肠病、结肠炎或克罗恩病中得到应用。 | ||||||
| 2 | 减少炎性反应的具有减少的脂磷壁酸的重组乳杆菌 | CN201180039874.2 | 2011-06-16 | CN103189504A | 2013-07-03 | T.R.克莱恩哈默; E.普菲勒; M.莫哈马扎德 |
| 提供用于治疗或预防炎性病症的方法和组合物。本发明组合物包含经遗传修饰以减少细胞表面上脂磷壁酸展示的重组细菌。本发明方法包括给予受试者经修饰以减少细胞表面上脂磷壁酸展示的重组细菌。给予所述重组细菌促进所需的治疗反应。所述重组细菌可以以单独剂量或系列剂量给予。本发明方法在治疗或预防多种炎性病症包括，例如，治疗或预防炎性肠病、结肠炎或克罗恩病中得到应用。 | ||||||
| 3 | Lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses | US15097524 | 2016-04-13 | US09980992B2 | 2018-05-29 | Todd R. Klaenhammer; Erika Pfeiler; Mansour Mohamadzadeh |
| Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease. | ||||||
| 4 | RECOMBINANT LACTOBACILLUS WITH DECREASED LIPOTEICHOIC ACID TO REDUCE INFLAMMATORY RESPONSES | US15097524 | 2016-04-13 | US20160324905A1 | 2016-11-10 | Todd R. Klaenhammer; Erika Pfeiler; Mansour Mohamadzadeh |
| Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease. | ||||||
| 5 | Recombinant Lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses | US13805037 | 2011-06-16 | US09340792B2 | 2016-05-17 | Todd R. Klaenhammer; Erika Pfeiler; Mansour Mohamadzadeh |
| Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease. | ||||||
| 6 | RECOMBINANT LACTOBACILLUS WITH DECREASED LIPOTEICHOIC ACID TO REDUCE INFLAMMATORY RESPONSES | US13805037 | 2011-06-16 | US20130224153A1 | 2013-08-29 | Todd R. Klaenhammer; Erika Pfeiler; Mansour Mohamadzadeh |
| Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease. | ||||||
| 7 | RECOMBINANT LACTOBACILLUS WITH DECREASED LIPOTEICHOIC ACID TO REDUCE INFLAMMATORY RESPONSES | EP11728137.8 | 2011-06-16 | EP2582800A1 | 2013-04-24 | KLAENHAMMER, Todd, R.; PFEILER, Erika; MOHAMADZADEH, Mansour |
| Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease. | ||||||
| 8 | RECOMBINANT LACTOBACILLUS WITH DECREASED LIPOTEICHOIC ACID TO REDUCE INFLAMMATORY RESPONSES | EP11728137.8 | 2011-06-16 | EP2582800B1 | 2016-11-09 | KLAENHAMMER, Todd, R.; PFEILER, Erika; MOHAMADZADEH, Mansour |
| Methods and compositions for treating or preventing inflammatory disorders are provided. The compositions of the invention comprise a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. Methods of the invention comprise administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods of the invention find use in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease. | ||||||
| 9 | 炎症応答を減少させるための、リポテイコ酸が減少した組み換えラクトバチルス | JP2017109331 | 2017-06-01 | JP2017153485A | 2017-09-07 | トッド アール. クレーンハンマー; エリカ ファイラー; マンスール モハマザデ |
| 【課題】炎症応答を減少させるための、リポテイコ酸が減少した組み換えラクトバチルスを提供すること。 【解決手段】炎症性障害を処置または予防するための方法および組成物が提供される。本発明の組成物は、細胞表面のリポテイコ酸の提示を減少させるように遺伝子改変された組換え体細菌を含む。本発明の方法は、細胞表面のリポテイコ酸の提示を減少させるように改変された組換え体細菌を被験体に投与することを含む。組換え体細菌の投与は、所望の治療的応答を促進する。組換え体細菌は、単一の用量または一連の用量で投与することができる。本発明の方法は、例えば炎症性腸疾患、大腸炎またはクローン病を処置または予防することを含む、様々な炎症性障害を処置または予防することにおいて有益である。 【選択図】なし |
||||||
| 10 | 炎症応答を減少させるための、リポテイコ酸が減少した組み換えラクトバチルス | JP2013515509 | 2011-06-16 | JP6154320B2 | 2017-07-05 | クレーンハンマー, トッド アール.; ファイラー, エリカ; モハマザデ, マンスール |
| 11 | To reduce the inflammatory response, a recombinant Lactobacillus that lipoteichoic acid was reduced | JP2013515509 | 2011-06-16 | JP2013537402A | 2013-10-03 | トッド アール． クレーンハンマー，; エリカ ファイラー，; マンスール モハマザデ， |
| 炎症性障害を処置または予防するための方法および組成物が提供される。 本発明の組成物は、細胞表面のリポテイコ酸の提示を減少させるように遺伝子改変された組換え体細菌を含む。 本発明の方法は、細胞表面のリポテイコ酸の提示を減少させるように改変された組換え体細菌を被験体に投与することを含む。 組換え体細菌の投与は、所望の治療的応答を促進する。 組換え体細菌は、単一の用量または一連の用量で投与することができる。 本発明の方法は、例えば炎症性腸疾患、大腸炎またはクローン病を処置または予防することを含む、様々な炎症性障害を処置または予防することにおいて有益である。 | ||||||
QQ群二维码
意见反馈
意见反馈